Roche Resources is intended for UK Healthcare Professionals only. By entering this site you are confirming that you are a UK Healthcare professional.


POLIVY in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL).1

 

POLIVY in combination with bendamustine and rituximab is indicated for the treatment of adult patients with relapsed/refractory (R/R) DLBCL who are not candidates for haematopoietic stem cell transplant.1

nil
Prescribing Information
Treatment pathway 1L: POLIVY

NICE recommends and SMC accepts POLIVY+R-CHP for untreated diffuse large B-cell lymphoma (DLBCL) 2,3

Polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) can be used as an option to treat previously untreated DLBCL in adults when:

  • they have an International Prognostic Index (IPI) score of 2 to 5

In the UK, approximately 5,500 patients are diagnosed with DLBCL per year.4 Effective treatment at first line (1L) is the best opportunity to achieve a successful outcome in DLBCL.5,6

 

POLIVY+R-CHP was the first treatment in over 20 years showing superiority over
R-CHOP, offering longer progression-free survival (PFS) and a generally comparable safety profile.7

 

POLARIX was the first phase III study in 20 years with a significant improvement in PFS and EFSeff over R-CHOP in previously untreated DLBCL.7
Expert perspectives on the POLARIX trial data

 

Watch the videos below to hear the views of Professor Graham Collins, Consultant Haematologist, The Churchill Hospital, Oxford, on the POLARIX trial data and its implications for UK clinical practice.

 

For UK prescribing information, please click here or scan the QR code in the videos.

We are dedicated to supporting HCPs to achieve optimal patient outcomes, If you have any questions about our products, from practical matters to understanding the data, please do not hesitate to contact us.

 

Contact our team to discuss POLIVY
Explore more
Content page
Discover more via our other promotional page that include Roche products.
Products Content page
Review the use of monotherapy treatments for R/R DLBCL via our other promotional page that includes Roche products.
Hematology Oncology Content page
Explore the Roche haematology portfolio

Abbreviations:


1L, first-line; DLBCL, diffuse large B-cell lymphoma; EFSeff, event-free survival for efficacy causes; HCP, healthcare professional; NICE, National Institute for Health and Care Excellence; PFS, progression free survival; R-CHP, rituximab, cyclophosphamide, doxorubicin, prednisone; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; R/R, relapsed/refractory; SMC, Scottish Medicines Consortium.

References:

  1. POLIVY Summary of Product Characteristics.
  2. NICE Technology appraisal gudiance TA874. Published: 01 March 2023. Available at https://www.nice.org.uk/guidance/ta874. Accessed: March 2026.
  3. SMC2525. Published 05 May 2023. Available at: https://scottishmedicines.org.uk/media/7614/polatuzumab-vedotin-polivy-final-may-2023-for-website.pdf. Accessed: March 2026.
  4. Cancer Research UK. Diffuse Large B-Cell Lymphoma. Available at: https://www.cancerresearchuk.org/about-cancer/non-hodgkin-lymphoma/types/diffuse-large-B-cell-lymphoma. Accessed: March 2026.
  5. Maurer MJ, Ghesquières H, et al. J Clin Oncol. 2014;32(10):1066–1073.
  6. Nowakowski GS. Clin Adv Hematol Oncol. 2021;19(5):284–287.
  7. Tilly H, et al. N Engl J Med. 2022;386(4):351–363.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. You can also report via the free Yellow Card app available from the Apple App Store or Google Play Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554. Adverse reactions should be reported by brand name and batch number.
You are about to leave the rocheresources.co.uk environment and will be redirected to another site or resource which may contain information not intended for a UK audience. Roche Products Limited does not endorse or accept liability for sites or resources controlled by third parties.